Givosiran

Quote






anonymous said:
There is no way you work for Alnylam, this is clearly amateur opposition "psy-ops" shit. The reality is that there have been very few discontinuations on the medication and when dealing with an incredibly sick population to start with, SAE's are going to happen.
Click to expand...

JG,

Your panties are showing. Man, we ALL know that this is you responding. Please, can you just walk away from the computer? Surely your espionage classes at the Academy drummed some sense into your head? This isn't the best approach....
 












anonymous said:
Did you even read the article? Trial was stopped due to suspect increased peripheral neuropathy, the excess mortality was discovered after unblinding.
Click to expand...

apparently your reading comprehension is challenged, JG. The DMC met to review neuropathy signals, but the study was stopped due to “a benefit risk profile that no longer supported dosing.” That was the excess mortality. The company would never see any data prior to unblinding.

Following recent reports in the Phase 2 OLE study of new onset or worsening peripheral neuropathy, the ENDEAVOUR DMC assembled yesterday at the Company's request to review these reports and ENDEAVOUR data on an unblinded basis. The DMC did not find conclusive evidence for a drug-related neuropathy signal in the ENDEAVOUR trial, but informed the Company that the benefit-risk profile for revusiran no longer supported continued dosing. The Company subsequently reviewed unblinded ENDEAVOUR data which revealed an imbalance of mortality in the revusiran arm as compared to placebo.
 






anonymous said:
apparently your reading comprehension is challenged, JG. The DMC met to review neuropathy signals, but the study was stopped due to “a benefit risk profile that no longer supported dosing.” That was the excess mortality. The company would never see any data prior to unblinding.

Following recent reports in the Phase 2 OLE study of new onset or worsening peripheral neuropathy, the ENDEAVOUR DMC assembled yesterday at the Company's request to review these reports and ENDEAVOUR data on an unblinded basis. The DMC did not find conclusive evidence for a drug-related neuropathy signal in the ENDEAVOUR trial, but informed the Company that the benefit-risk profile for revusiran no longer supported continued dosing. The Company subsequently reviewed unblinded ENDEAVOUR data which revealed an imbalance of mortality in the revusiran arm as compared to placebo.
Click to expand...

Perfect example of the unwillingness to accept limitations of RNAi therapy and the reality of the underlying and unanswered safety concerns.
 






Look at our stock you worthless POS. Clearly we know what we are doing and the plan is working.

I think you have gone silent because your options have jumped and all of a sudden everything is fine.

Loser
 






anonymous said:
Look at our stock you worthless POS. Clearly we know what we are doing and the plan is working.

I think you have gone silent because your options have jumped and all of a sudden everything is fine.

Loser
Click to expand...

better take the money and run. just a matter of time before promotion tactics are revealed and/or people start dropping like due to cardiac issues. think about it, even in our own internal KOL presentations, the doctors who speak say they have no idea what the downstream effect of “shutting of the faucet” for these proteins will have on patients.
 






anonymous said:
better take the money and run. just a matter of time before promotion tactics are revealed and/or people start dropping like due to cardiac issues. think about it, even in our own internal KOL presentations, the doctors who speak say they have no idea what the downstream effect of “shutting of the faucet” for these proteins will have on patients.
Click to expand...

Ok, I have to call you out. Please stop baiting him! He's proven that he can't help himself. You've made your point.
 






























You trolls who are being so negative - go pound sand. Go back to primary care - Alnylam does more for patients then you have ever done. It's so foul that anyone would come here - complain about what this company has invested. No company is perfect however if you are miserable here - take your toxic entitlement somewhere else.
 












Top Bottom
Back
Quote